Top Page
BioMark Diagnostics
(BUX)
BioMark Diagnostics (BUX) vs. iShares MSCI Canada ETF (EWC)
BioMark Diagnostics Business Overview & Revenue Model
BioMark Diagnostics Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2024 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 123.42K | 163.22K | 154.22K | 153.49K | 43.93K | 0.00 |
| Gross Profit | 36.92K | 163.22K | 154.22K | -232.70K | 43.93K | -13.69K |
| EBITDA | -1.14M | -919.05K | -1.46M | -1.35M | -1.22M | -1.08M |
| Net Income | -1.65M | -1.43M | -1.93M | -1.84M | -1.45M | -1.09M |
Balance Sheet | ||||||
| Total Assets | 1.88M | 1.09M | 3.13M | 732.29K | 1.47M | 952.94K |
| Cash, Cash Equivalents and Short-Term Investments | 1.55M | 156.75K | 2.48M | 72.04K | 382.71K | 877.68K |
| Total Debt | 153.22K | 1.55M | 454.16K | 823.87K | 1.05M | 119.32K |
| Total Liabilities | 1.01M | 1.70M | 1.39M | 1.88M | 2.11M | 1.03M |
| Stockholders Equity | 863.47K | -609.61K | 1.74M | -1.15M | -635.69K | -79.09K |
Cash Flow | ||||||
| Free Cash Flow | -1.42M | -986.91K | -1.10M | -919.72K | -1.26M | -455.55K |
| Operating Cash Flow | -1.41M | -982.52K | -1.09M | -914.42K | -1.20M | -455.55K |
| Investing Cash Flow | -835.83K | -4.39K | -3.53K | -5.30K | -59.20K | -3.20K |
| Financing Cash Flow | 2.93M | 1.07M | 3.42M | 609.05K | 768.16K | 724.63K |
BioMark Diagnostics Technical Analysis
BioMark Diagnostics Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | C$49.39M | -29.94 | ― | ― | -21.89% | 26.36% | |
45 Neutral | C$427.12M | -9.68 | ― | ― | 34.85% | -62.50% | |
44 Neutral | C$4.52M | -1.66 | -9999.00% | ― | ― | 19.05% | |
40 Underperform | C$55.37M | -17.43 | -2846.90% | ― | ― | 10.97% |
BioMark Diagnostics Corporate Events
BioMark Diagnostics has achieved a key validation milestone with the acceptance of its machine learning-driven lung cancer detection research for publication in the peer-reviewed journal Frontiers in Oncology. Developed in collaboration with Harrisburg University of Science and Technology, the study demonstrates that leveraging pathway-based plasma metabolomic biomarkers and interpretability tools such as SHAP analysis can enhance diagnostic accuracy and deepen understanding of the metabolic mechanisms underlying early-stage lung cancer. The publication provides third-party confirmation of BioMark’s long-term investment in AI infrastructure and metabolomic pathway analysis, strengthening its credibility at a time when investors and the healthcare industry are demanding robust proof of concept for AI-enabled medical technologies and reinforcing its positioning at the intersection of oncology, metabolomics and advanced data science.
The most recent analyst rating on (TSE:BUX) stock is a Hold with a C$0.45 price target. To see the full list of analyst forecasts on BioMark Diagnostics stock, see the TSE:BUX Stock Forecast page.
BioMark Diagnostics has achieved a key validation milestone with the acceptance of its machine learning-driven lung cancer detection research for publication in the peer-reviewed journal Frontiers in Oncology. Developed in collaboration with Harrisburg University of Science and Technology, the study demonstrates that leveraging pathway-based plasma metabolomic biomarkers and interpretability tools such as SHAP analysis can enhance diagnostic accuracy and deepen understanding of the metabolic mechanisms underlying early-stage lung cancer. The publication provides third-party confirmation of BioMark’s long-term investment in AI infrastructure and metabolomic pathway analysis, strengthening its credibility at a time when investors and the healthcare industry are demanding robust proof of concept for AI-enabled medical technologies and reinforcing its positioning at the intersection of oncology, metabolomics and advanced data science.
The most recent analyst rating on (TSE:BUX) stock is a Hold with a C$0.45 price target. To see the full list of analyst forecasts on BioMark Diagnostics stock, see the TSE:BUX Stock Forecast page.
BioMark Diagnostics reported a transformative 2025 marked by major capacity expansion, clinical validation and growing industry recognition, as it doubled laboratory throughput, bolstered its technical team, advanced AI/ML capabilities, and completed Canada’s largest lung cancer diagnostic study involving more than 7,000 patients. The company was selected as the exclusive partner for the 10,000-patient HANSE lung cancer trial, submitted ISO 15189 documentation to support future U.S. CLIA/CAP accreditation, secured over $4.5 million in capital plus multiple government and foundation grants, and gained visibility through peer-reviewed publications and awards, collectively strengthening its commercialization prospects, international expansion, and appeal to both traditional and impact-focused investors ahead of key 2026 milestones in regulatory approvals, lab services launch and strategic partnerships.
The most recent analyst rating on (TSE:BUX) stock is a Hold with a C$0.49 price target. To see the full list of analyst forecasts on BioMark Diagnostics stock, see the TSE:BUX Stock Forecast page.
BioMark Diagnostics has appointed technology investor and AI-focused growth strategist James Lavender to its board of directors following approval at the company’s recent annual general meeting. Lavender, a major participant in BioMark’s March 2025 financing round, has been closely involved in advancing the company’s U.S. market entry, helping to establish connections with state-level bodies and strategic investment groups, while also championing broader use of artificial intelligence and machine learning to scale BioMark’s metabolomics-based oncology diagnostics. Management expects his software, enterprise sales and U.S. market development experience to support the company’s transition from development to commercial execution, strengthen its commercialization roadmap, and accelerate the expansion of its lab services footprint in the United States.
The most recent analyst rating on (TSE:BUX) stock is a Hold with a C$0.49 price target. To see the full list of analyst forecasts on BioMark Diagnostics stock, see the TSE:BUX Stock Forecast page.
BioMark Diagnostics Inc. has begun the process to obtain ISO 15189 accreditation for its medical laboratory in Quebec City through the Standards Council of Canada, with the accreditation program officially launched on December 19, 2025 and a site visit expected in early 2026. The move represents a key step in the company’s shift from an R&D-focused operation to a commercial-stage diagnostic business, as ISO 15189 is expected to facilitate access to global markets, support strategic partnerships and licensing deals, and reassure hospitals, biopharma partners and payors about the quality and reliability of its mass spectrometry-based liquid biopsy assays. Following ISO 15189, BioMark plans to pursue CLIA and CAP accreditations to serve the U.S. cancer diagnostics market with its laboratory-developed tests, underscoring its broader commercialization and international expansion strategy.
The most recent analyst rating on (TSE:BUX) stock is a Hold with a C$0.49 price target. To see the full list of analyst forecasts on BioMark Diagnostics stock, see the TSE:BUX Stock Forecast page.
BioMark Diagnostics Inc. and its research partners have been honored with the Innovation Award at the ADRIQ Innovation Awards Gala for their collaborative lung cancer screening project. This recognition underscores the successful development of a multimodal approach that combines blood biomarker analysis with clinical data using AI to predict lung cancer risk. The project, supported by significant funding and strategic partnerships, validates BioMark’s core technology and commercialization strategy, paving the way for international expansion and enhanced precision diagnostics access.
The most recent analyst rating on (TSE:BUX) stock is a Hold with a C$0.40 price target. To see the full list of analyst forecasts on BioMark Diagnostics stock, see the TSE:BUX Stock Forecast page.
BioMark Diagnostics Inc. is aligning with the Canadian Cancer Society’s 2026-2035 Pan-Canadian Lung Cancer Action Plan to reduce lung cancer mortality by 30% over the next decade. The company aims to expand access to its AI-enabled biomarker testing, which complements existing screening methods and addresses diagnostic barriers in underserved regions, thereby enhancing early-stage cancer detection and transforming patient outcomes across Canada.
The most recent analyst rating on (TSE:BUX) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on BioMark Diagnostics stock, see the TSE:BUX Stock Forecast page.